Belgian crop-protection developer Biotalys says the Netherlands has authorised large-scale demonstration trials of its next-generation protein-based biofungicide candidate EVOCA NG, covering a combined maximum of 350 hectares across three horticultural crops. The company announced the decision on 3 November 2026.
According to Biotalys, the permission from the Dutch Board for the Authorisation of Plant Protection Products and Biocides (Ctgb) covers up to 150 hectares of tomatoes, 150 hectares of cucumbers and 50 hectares of strawberries. These figures are upper limits for authorised demonstrations, not evidence that 350 hectares have already been sprayed, enrolled or planted for the trials.
Demonstration approval, not a general product licence
The planned programme is designed to evaluate EVOCA NG against Botrytis, which causes grey mould, and powdery mildew under commercial growing conditions. The company says produce from permitted trial plots may enter the food chain subject to the trial conditions.
Crucially, the demonstration permission is not full Dutch or European product registration. EVOCA NG remains a candidate undergoing development and regulatory review. Biotalys has separately developed a first-generation product, EVOCA, and says experience with that earlier product informed its demonstration programme; results from EVOCA must not automatically be presented as results for EVOCA NG.
The company did not identify a public Ctgb decision reference in its announcement, so the regulatory approval and trial scope are reported here as Biotalys’s account rather than as independently checked decision conditions.
Why greenhouse operators are watching
For protected-crop growers, additional disease-control options would be commercially relevant if they demonstrate consistent performance, acceptable residues and workable integration into existing spray programmes. Fungal pathogens can threaten crop quality and yields, while the available chemical-control toolkit faces regulatory and resistance pressures.
Biotalys cites positive grower experience with its earlier EVOCA trials on strawberries. Those statements describe the first-generation product and do not establish the outcome of the newly authorised EVOCA NG evaluations. Demonstration programmes can inform a grower’s future procurement choices, but they do not replace comparative efficacy, cost and residue data.
What remains to be established
The actual area enrolled, participating growers, final trial conditions and independently reviewed results have not been reported. Neither has a definitive date for broad commercial sale. The next useful signals will be the realised trial scale, measured performance across crops and formal regulatory registration progress.